A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

NCT07190716 ↗

Phase 1 Not yet recruiting 36 enrolled Genrix (Shanghai) Biopharmaceutical Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary pharmacodynamic characteristics of GR2301 injection in healthy adult subjects in China.The GR2301 injection dosage will be gradually increased. All healthy subjects will receive a single subcutaneous injection. Following administration, subjects will be followed for at least 16 weeks ± 7 days.

Timeline

Start: 2025-10-10
Primary completion: 2026-05-30
Completion: 2026-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GR2301 injection	Unknown	—	Subcutaneous

Indications

No indication recorded.